Xiaochen Zhang
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Addressing Obesity to Reduce Cancer Risk and Health Disparities in Underserved Populations
Open Date: 2020-08-01
Close Date: 2022-07-31
Articles (21)
We developed calibration equations using metabolomics from fasting blood and 24-hour urine for Healthy Eating Index 2010 (HEI-2010) and Alternative Healthy Eating Index 2010 (AHEI-2010) to address measurement error from self-reported diet. We examined associations between metabolomic-calibrated dietary patterns and cancer risk in the Women’s Health Initiative (WHI, n=108,522). Metabolomic signatures were created from a WHI Feeding (n=153;2010-2014) and WHI Observational Study (n=450;2006-2009). Dietary patterns were regressed on metabolites using the feeding study food intake records. Metabolomic-based dietary patterns were estimated from 24-hour dietary recalls, FFQ and 4DFR in the Observational Study using a stepwise approach. Cox regression estimated cancer risk of metabolomic-calibrated dietary patterns with a median follow-up of 15.8 years. Adjusted R2 for HEI-2010 and AHEI-2010 calibration equations were 57.5% and 48.8% for FFQ, 61.6% and 62.6% for 4DFR, and 52.5% and 53.2% for dietary recalls. Without calibration, a 20% increment in HEI-2010 was associated with lower risk of colorectal (HR=0.94, 95% CI=0.90-0.99), lung (HR=0.90, 95% CI=0.86-0.94), bladder (HR=0.86, 95% CI=0.75-0.99), and total invasive cancers (HR=0.98, 95% CI=0.96-0.99). With metabolomic calibration, higher HEI-2010 was associated with lower risk of lung (HR=0.79, 95% CI=0.71-0.88) and total invasive cancers (HR=0.96, 95% CI=0.92-1.00). Metabolomic-calibrated dietary patterns might mitigate measurement errors and strengthen diet-cancer associations.
Year:
2026
Background: Several studies early in the COVID-19 pandemic suggested that those with a cancer history had a higher risk of COVID-19 infections and complications. However, few prospective studies evaluated the association of cancer with COVID-19 in older women. We aimed to examine the association of cancer history with the risk of COVID-19 and various COVID-19 outcomes among older women. Methods: The Women’s Health Initiative is an ongoing cohort study that recruited 161,808 postmenopausal women of 50 to 79 years of age from 1993 to 1998. Those who completed the COVID-19 survey (2021–2022) were included (n = 35,623). Multivariable linear and logistic regressions were used to examine COVID-19 positivity, symptom severity, long COVID, and COVID concerns/anxiety outcomes. Results: Twenty-eight percent (n = 9,901) of participants had a history of cancer. Cancer history was not significantly associated with COVID-19 positivity [OR = 0.94; 95% confidence interval (CI), 0.81–1.08], COVID-19 hospitalization (OR = 1.21; 95% CI, 0.85–1.72), number of symptoms (least squares mean = 0.33; 95% CI, −0.20 to 0.85), and long COVID (OR = 1.18; 95% CI, 0.88–1.58). Conclusions: A history of cancer was not associated with most COVID-19 outcomes. Future studies should continue to examine physiologic mechanisms contributing to differences among cancer survivors and prioritize the inclusion of underserved populations to identify strategies to address the impact of COVID-19. Impact: These findings may assure cancer survivors that their diagnosis alone does not increase their risk of COVID-19 and suggest that older women with a history of cancer may have similar risks of COVID-19 outcomes compared with their noncancer counterparts.
Year:
2025
Background The impact of COVID‐19 on physical function (PF) outcomes among older adults remains unclear. We examined the long‐term association between COVID, PF, and Activities of Daily Living (ADLs) among women from the Women's Health Initiative (WHI). Methods Participants from the WHI who completed the COVID‐19 survey (2021–2022) and annual survey (2022) were included. Self‐reported data on COVID‐19 testing and symptoms (2021–2022) were used. PF score and ADLs were evaluated pre‐ and post‐COVID‐19 survey by the 36‐Item Short Form Survey PF subscale, the Lawton Instrumental Activities of Daily Living, and the Katz Index of Independence in ADL. Multivariable linear regression and logistic regression were used and adjusted for pre‐COVID functioning to examine the association between COVID status, PF, and ADLs. The interaction between pre‐COVID functioning and COVID status was tested. Results Among the 13,933 WHI participants, 71.4% were aged ≥ 80 years, and 88.6% were Non‐Hispanic White. Only 8.7% tested positive for COVID‐19 ( n = 1210), with 35.1% having long COVID ( n = 425). The most common long COVID symptoms were fatigue (18.2%), malaise (12.2%), memory problems (12.1%), and brain fog (11.2%). Women who tested COVID+ had lower PF scores (60 vs. 65, p = 0.045) and were less likely to be able to do all ADLs without help (74% vs. 79.2%, p = 0.015) compared to those who never tested COVID+. After controlling for covariates, post‐COVID PF scores did not differ by COVID status ( p = 0.30), although pre‐COVID PF scores were significantly linked to post‐COVID scores ( p < 0.001). Similarly, the odds of being able to do all ADLs without any help did not differ by COVID status ( p = 0.31), with pre‐COVID ADLs significantly associated with post‐COVID ADLs ( p < 0.001). Conclusions In older women, after accounting for pre‐COVID functional status, the association between long COVID and lower functioning became nonsignificant. Our findings highlight the importance of preserving physical functioning among older women.
Year:
2025
Social support plays a key role in behavioral changes, especially in Appalachian populations. We examined the mediating effect of social support in behavioral changes and corresponding weight loss outcomes among Appalachian adults. Data were from a group-randomized trial that compared a 12-month faith-based weight loss intervention to an active control group among overweight Appalachian adults in churches. Participants from the weight loss intervention who completed the 12-month assessment were the focus of this analysis. Baseline and 12-month data on weight, social support for eating habits (SSEH) and physical activity (SSPA) from family, friends, and church family, physical activity, and dietary intake were collected. Logistic and linear regression models evaluated mediating effects of SSEH and SSPA on the association between intervention attendance and behavioral changes and corresponding weight loss outcomes. Most participants ( n = 243) were female (76.2%), white (97.5%), and married or living with a partner (81.2%). After the 12-month intervention, participants lost weight (1.1 ± 0.3 kg), increased fruit and vegetable intake (0.4 ± 0.1servings/day), reduced caloric intake (322.9 ± 42.2 kcal/day), improved SSEH from family, and increased SSPA from the church family (all P < 0.05). Increased SSEH from family mediated 62% of the association between intervention attendance and fruit and vegetable servings per day. Each 100 kcal decrease in caloric intake was associated with decreased weight and BMI at 12-months (0.2 ± 0.1 kg, P = 0.003; 0.1 ± 0.02 kg/m 2 , P = 0.002). Our study demonstrated the mediation effect of social support for healthy eating on the association between intervention attendance and fruit and vegetable intake, which underscored the critical role of social support and calorie intake among Appalachian populations in losing weight. The study was pre-registered at clinicaltrials.gov (#NCT02121691).
Year:
2025
Background: Several studies early in the COVID-19 pandemic suggested that those with a cancer history had a higher risk of COVID-19 infections and complications. However, few prospective studies evaluated the association of cancer with COVID-19 in older women. We aimed to examine the association of cancer history with the risk of COVID-19 and various COVID-19 outcomes among older women. Methods: The Women’s Health Initiative is an ongoing cohort study that recruited 161,808 postmenopausal women of 50 to 79 years of age from 1993 to 1998. Those who completed the COVID-19 survey (2021–2022) were included ( n = 35,623). Multivariable linear and logistic regressions were used to examine COVID-19 positivity, symptom severity, long COVID, and COVID concerns/anxiety outcomes. Results: Twenty-eight percent ( n = 9,901) of participants had a history of cancer. Cancer history was not significantly associated with COVID-19 positivity [OR = 0.94; 95% confidence interval (CI), 0.81–1.08], COVID-19 hospitalization (OR = 1.21; 95% CI, 0.85–1.72), number of symptoms (least squares mean = 0.33; 95% CI, −0.20 to 0.85), and long COVID (OR = 1.18; 95% CI, 0.88–1.58). Conclusions: A history of cancer was not associated with most COVID-19 outcomes. Future studies should continue to examine physiologic mechanisms contributing to differences among cancer survivors and prioritize the inclusion of underserved populations to identify strategies to address the impact of COVID-19. Impact: These findings may assure cancer survivors that their diagnosis alone does not increase their risk of COVID-19 and suggest that older women with a history of cancer may have similar risks of COVID-19 outcomes compared with their noncancer counterparts.
Year:
2025
Supplemental Table 1. Criteria for metabolic phenotype classification. HDL high density lipoprotein cholesterol; HOMA-IR Homeostatic Model Assessment for Insulin Resistance ; hs-CRP high sensitive C-reactive protein
Year:
2025
Supplemental Figure 7. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Women’s Health Initiative. Model adjusted for demographics (age, education, race/ethnicity, marital status), lifestyle (smoking status, physical activity, alcohol use, fruits and vegetable intake, fiber intake, read meat intake), hormonal factors for female cancers (parity, hormone therapy use), family history of ORC and study ID. MUNW=metabolically unhealthy normal weight; MHO=metabolically healthy overweight/obese; MUO= metabolically unhealthy overweight/obese. Metabolically healthy normal weight (MHNW) is the comparison group.
Year:
2025
Supplemental Figure 5. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by ATP III criteria with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Women’s Health Initiative. Model adjusted for demographics (age, education, race/ethnicity, marital status), lifestyle (smoking status, physical activity, alcohol use, fruits and vegetable intake, fiber intake, read meat intake), hormonal factors for female cancers (parity, hormone therapy use), family history of ORC and study ID. MUNW=metabolically unhealthy normal weight; MHO=metabolically healthy overweight/obese; MUO= metabolically unhealthy overweight/obese. Metabolically healthy normal weight (MHNW) is the comparison group.
Year:
2025
Supplemental Table 5. Association between metabolic phenotypes defined by high sensitivity C-Reactive Protein (hs-CRP) ≥ 10 mg/L with obesity-related cancer risk in the Women’s Health Initiative cohort (N= 21,245).
Year:
2025
Supplemental Figure 4. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by the Wildman criteria with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Women’s Health Initiative. Model adjusted for demographics (age, education, race/ethnicity, marital status), lifestyle (smoking status, physical activity, alcohol use, fruits and vegetable intake, fiber intake, read meat intake), hormonal factors for female cancers (parity, hormone therapy use), family history of ORC and study ID. MUNW=metabolically unhealthy normal weight; MHO=metabolically healthy overweight/obese; MUO= metabolically unhealthy overweight/obese. Metabolically healthy normal weight (MHNW) is the comparison group.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (27)
Shama Karanth
Assistant Professor
University of Florida
Marc Gunter
International Agency for Research on Cancer
Garnet Anderson
Fred Hutchinson Cancer Research Center
Trang VoPham
Associate Professor
University of Washington
Aladdin Shadyab
Associate Professor
University of California, San Diego
Fred Tabung
University of South Carolina
Linda Van Horn
Professor
Northwestern University Feinberg School of Medicine
Marian Neuhouser
Professor
Fred Hutchinson Cancer Research Center
Electra D. Paskett
Ohio State University
Mohamed Elsaid
Assistant Professor
The Ohio State University College of Medicine
Mary Playdon
Assistant Professor
University of Utah
Chloe Hery
Ohio State University
Rebecca Seguin-Fowler
Associate Professor
Texas A&M University
Sheetal Hardikar
University of Utah
Cynthia A. Thomson
-
Jean Wactawki-Wende
Dean, Suny Distinguished Professor
University at Buffalo
Scott Summers
Co-Director
University of Utah
Diane Von Ah
Distinguished Professor of Cancer Research & Mildred E. Newton Endowed Professor
Ohio State University
Su Yon Jung
University of California, Los Angeles
William L. Holland
Associate Professor
University of Utah
Cheng Zheng
Associate Professor
University of Nebraska Medical Center
Yangbo Sun
Assistant Professor
University of Tennessee Health Science Center
Zachary Chaplow
Postdoctoral Researcher & Lecturer
Ohio State University
marcia stefanick
Stanford University
Ting-Yuan Cheng
Associate Professor
Ohio State University
Nazmus Saquib
-
Victoria DeScenza
Assistant Professor in Residence; Graduate Exercise Prescription Program Coordinator
University of Connecticut
Make your next move.
Prepare your application
Review drafts before you send them.